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Contraception is one of the most important tools for development 
in any country, as it has a profound impact on individual, family and 
societal wellbeing.[1] Increasing contraception can lead to a reduction 
in maternal and child mortality and HIV/AIDS.[2] It contributes to 
economic growth by increasing universal education, promotion of 
gender equality and environmental sustainability, and ultimately 
reduces poverty and hunger.[3,4]
Improving sexual and reproductive health therefore remains 
a key development goal for the South African (SA) government, 
which has committed to making modern contraceptives more 
accessible to women by 2020[5] and ensuring universal access to 
sexual and reproductive healthcare by 2030.[6] In the SA public sector, 
contraceptives are provided without charge to women who need 
them. Nationally, contraceptive choice is enhanced by the availability 
of a wide range of options, which was boosted by the introduction 
of the subdermal implant (Implanon and Jadelle) in 2014.[7] The 
implant was introduced in an effort to increase access to long-acting 
reversible contraceptives (LARCs), which have been shown to be 
very effective family planning options, reducing the need for user 
adherence and relieving pressure on health facilities, as contacts with 
health workers are fewer.[8] However, there have been challenges with 
the roll-out of LARCs in SA.[9] Approximately 1% of sexually active 
women use intrauterine devices, and although the use of implants has 
increased to ~4% in recent years, there has been a sharp decline in 
their uptake.[10] Early and premature removals of implants are also on 
the increase, mainly as a result of intolerable side-effects.[9,11,12]
With the SA government seeking to expand contraceptive 
coverage to all women in need,[5,6] it is important that the economic 
and financial implications of scaling up family planning are fully 
understood. Previous estimates of the costs of scaling up family 
planning in SA have not taken into consideration the inherent system 
challenges that could ultimately make cost-effective interventions 
such as LARCs unaffordable.[13,14]
Objectives
To measure the financial impact of increasing the demand for 
modern contraceptive methods in the SA public health sector over a 
5-year time horizon. Focus was placed on the roll-out of the implant 
to show the financial impact of premature and early removals. To 
the best of our knowledge, such analyses were not done prior to the 
roll-out of any contraceptive methods in SA, and we aim to show 
the importance of financial considerations in the implementation 
of health interventions, particularly as the nation strives to attain 
universal health coverage.
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Background. Evidence-informed priority setting is vital to improved investment in public health interventions. This is particularly 
important as South Africa (SA) makes the shift to universal health coverage and institution of National Health Insurance.
Objectives. To measure the financial impact of increasing the demand for modern contraceptive methods in the SA public health sector. We 
estimated the total cost of providing contraceptives, and specifically the budgetary impact of premature removals of long-acting reversible 
contraceptives.
Methods. We created a deterministic model in Microsoft Excel to estimate the costs of contraception provision over a 5-year time horizon 
(2018 - 2023) from a healthcare provider perspective. Only direct costs of service provision were considered, including drugs, supplies and 
personnel time. Costs were not discounted owing to the short time horizon. Scenario analyses were conducted to test uncertainty.
Results. The base-case cost of current contraceptive use in 2018 was estimated to be ZAR1.64 billion (ZAR29 per capita). Injectable 
contraceptives accounted for ~47% of total costs. To meet the total demand for family planning, SA would have to spend ~30% more than 
the estimate for current contraceptive use. In the year 2023, the ‘current use’ of modern contraceptives would increase to ZAR2.2 billion, 
and fulfilling the total demand for family planning would require ZAR2.9 billion. The base-case cost of implantable contraceptives was 
estimated at ZAR54 million. Assuming a normal removal rate, the use of implants is projected to increase by 20% during the 5-year 
period between 2019 and 2023, with an estimated 46% increase in costs. The cost of early removal of Implanon NXT is estimated at 
ZAR75  million, with total contraception costs estimated at ZAR102 million in 2019, compared with ZAR56 million when a normal 
removal rate is applied.
Conclusions. The costs of scaling up modern contraceptives in SA are substantial. Early and premature removals of implantable 
contraceptives are costly to the nation and must be minimised. The government should consider conducting appropriate health technology 
assessments to inform the introduction of new public health interventions as SA makes the shift to universal health coverage by means of 
National Health Insurance.
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Methods
A deterministic model was developed in Excel 2013 (Microsoft, 
USA) to estimate the financial impact of contraceptive provision 
in the public sector, from a provider perspective. The analysis only 
considered modern contraceptive methods and was undertaken 
on the population of sexually active women aged 15 - 49 years (we 
combined the proportions of currently married and sexually active 
unmarried women). Baseline data on family planning, including 
the contraceptive prevalence rate, unmet need for family planning, 
demand for family planning and modern contraceptive use, were 
obtained from the 2016 South Africa Demographic and Health 
Survey.[10] Population estimates were from the Statistics South Africa 
mid-year population projections.[15]
Table 1 shows the parameters used in the analysis. We used a 
contraceptive prevalence rate (CPR) of 57% for all sexually active 
women. The Depo-Provera injectable was the most commonly used 
contraceptive (18%), and Jadelle was the least common at 0.4%. The 
unmet need for family planning was 18%. The combined demand for 
family planning, which is the sum of the unmet need and the CPR, 
was therefore 75%. In the analysis, the weighted total contraceptive 
use among married and unmarried sexually active women was used 
to estimate total costs.
With the population in the first year of analysis (2018) estimated at 
12.3 million for the public sector, the total number of women using 
contraceptives was 7.1 million, and the number with an unmet need 
for family planning was 2.2 million.
The annual cost of providing each contraceptive method is 
shown in Table 2. Included in the calculation were costs of drugs 
and supplies and personnel time. Drug costs were obtained from 
the National Department of Health Master Procurement Catalogue 
of February 2018.[17] Personnel costs were based on the SA public 
sector salary structure for medical personnel.[18] The assumptions on 
materials used and personnel time to administer each contraceptive 
method were based on similar analyses in the OneHealth tool[19] and 
WHO-CHOICE.[20]
An average cost for provision of modern contraception was 
calculated by applying the weighted totals from Table 1 for each 
contraceptive method to the associated annual cost, giving a figure 
of ZAR228.35 (Table 2). The total cost of current contraceptive 
use was calculated as the product of the number currently using 
contraceptives (Table 1) and the weighted total cost (ZAR228, 
Table 2). The cost of fulfilling the current need (met and unmet) for 
family planning was estimated by multiplying the average cost by the 
current demand for family planning.
The financial impact of LARCs considered the impact of 
implantable contraceptives (Jadelle and Implanon) under two 
scenarios: normal removal and premature removal. Normal removal 
means that Implanon is removed and replaced every 3 years and 
Jadelle every 5 years. Premature removal is when the implants are 
removed before the prescribed period. A conservative estimate of 
Table 1. Base-case parameters used in the model
Parameters Married Unmarried Total
Weighted 
total Source
Contraceptive use, % SADHS, 2016[10]
Condoms 8.8 24 14.6 25.5
Depo-Provera injectable 18.2 17 17.7 30.9
Nur-Isterate injectable, 2 months 5.7 9.1 7.0 12.2
Implanon NXT 2.97 4.23 3.51 6.1
Jadelle 0.33 0.47 0.39 0.7
IUCD/IUS 1.2 1.3 1.2 2.1
Oral contraceptive 8.4 4.9 7.1 12.4
Female sterilisation 7.7 2.8 5.8 10.1
Total 53.3 63.8 57.3 100
Parameters Estimate Source
CPR, % 57 SADHS, 2016[10]
Unmet need for family planning, % 18 SADHS, 2016[10]
Demand for family planning, % 75 SADHS, 2016[10]
Population of women aged 15 - 49 years (2018) 15 416 805 Stats SA, 2017[15]
Proportion of population using public health services, % 80 District Health Barometer, 2017[16]
Population growth rate 1.016 Stats SA, 2017[15]
Number currently using contraceptives 7 067 063 Authors’ calculation
Number with unmet need for family planning 2 220 020 Authors’ calculation
Number needing family planning 9 287 083 Authors’ calculation
IUCD = intrauterine contraceptive device; IUS = intrauterine system; CPR = contraceptive prevalence rate; SADHS = South Africa Demographic and Health Survey; Stats SA = Statistics South Africa.
Table 2. Annual cost of contraceptive methods used in the 
model (2018)
Contraceptive method Cost (ZAR)
Condoms 134.54
Depo-Provera injectable 210.68
Nur-Isterate injectable, 2 months 345.43
Implanon NXT 117.74
Jadelle 72.67
IUCD/IUS 150.38
Oral contraceptive 203.26
Female sterilisation 501.32
Total (average cost) 228.35
IUCD = intrauterine contraceptive device; IUS = intrauterine system.
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50%[21] was applied for early removal, and costs were calculated 
for the combination of early removals and normal removals. The 
removal rate was assumed to be the same for Implanon and Jadelle. 
It  was further assumed that a patient whose implant had been 
removed would transfer to another modern contraceptive method, 
so the average cost for all contraceptives was added to the average 
cost for Implanon and Jadelle, resulting in an average cost for early 
removal of ZAR314.85 and ZAR117.74, respectively.
Contraceptive prevalence was assumed to increase at a rate of 
0.03% per year.[10] An annual rate of 1.6% was used to project the 
growth in the population over time.[15] Costs were not discounted, 
given the short time horizon, and all base case costs are presented in 
2018 prices. An annual inflation increment of 5% was assumed over 
the 3-year time horizon.
Results
Base-case costs of family planning
The total cost for all current contraceptive use in the public sector 
(for the year 2018) was estimated to be ZAR1.61 billion, a product of 
the average cost and the total number currently using contraceptives 
(Table 3). The model projected that injectables, Depo-Provera 
(ZAR460 million) and Nur-Isterate (ZAR298 million) would be the 
most costly, together accounting for ~47% of total costs. Condoms 
would cost ZAR242 million, and the Jadelle implant would cost 
the least at ZAR3.5 million. If the total demand for family planning 
was met (not shown in Table 3), total annual costs would rise to 
ZAR2.1 billion (~30% of current use costs).
Future changes in demand and costs of family planning
From an estimated 12.3 million in 2018, the number of women 
aged 15 - 49 years was projected to increase to 13.4 million in 2023 
(Table 4). Of these women, 7.9 million would be using modern 
contraceptives, with the CPR estimated at 58.8%. Maintaining the 
demand for family planning at 75%, the total demand for family 
planning would be ~10.1 million in 2023. The total cost associated 
with contraceptive use in that year would be ZAR2.29 billion (met 
need), and the total cost of fulfilling the demand (met and unmet) for 
family planning would be ZAR2.93 billion.
The budget impact of LARCs
In the base-case scenario (2018), we estimated that 433 000 women 
were using Implanon and 48 000 were using Jadelle (not included in 
Table 4). The total demand for Implanon was estimated to be 567 000 
and that for Jadelle 63 000. The projected total cost of ‘current use’ 
of Implanon was ZAR81.69 million and the total cost of fulfilling 
the demand for family planning was ZAR184.67 million. Jadelle was 
projected to have a much smaller impact owing to lower utilisation 
numbers and lower average cost; ZAR5.6 million for ‘current use’ and 
ZAR6.4 million for fulfilling the total demand.
Assuming that all LARCs were removed at a normal rate between 
2019 and 2023, the number using implantable contraceptives is 
projected to increase by 20% (from 453 000 to 543 000 for Implanon 
and from 50 000 to 60 000 for Jadelle), while the total demand for all 
contraceptives would increase by about 7% (Table 5). At this usage 
rate, the total cost of providing the implants (both Implanon and 
Jadelle) is estimated to be ZAR59 million in 2019 and ZAR87 million 
in 2023 (a 46% increase).
Table 6 shows the impact of early removals on the cost of 
Implanon. Assuming a 50% premature removal rate, the number 
of users decreases by 50%, e.g. in 2019 to 226 534 (from 453 069 
as given in Table 5). The cost of early removal is estimated to be 
ZAR74.9 million in 2019. Added to the cost of normal removal, the 
total cost of Implanon in 2019 is ZAR102.9 million. This is 1.8 times 
more than the cost without premature removals estimated in Table 5.
Table 3. Costs of current contraceptive use (ZAR), 2018
Contraceptive method Number using Unit cost Cost per method
Condoms 1 800 683 134.54 242 269 349
Depo-Provera injectable 2 183 020 210.68 459 926 426
Nur-Isterate injectable, 2 months 863 341 345.43 298 225 981
Implanon NXT 432 904 117.74 50 971 594
Jadelle 48 100 72.67 3 495 462
IUCD/IUS 148 001 150.38 22 256 095
Oral contraceptive 875 675 203.26 177 987 269
Female sterilisation 715 340 501.32 358 615 794
Total 7 067 063 228.35 1 613 747 969
IUCD = intrauterine contraceptive device; IUS = intrauterine system.
Table 4. Changes in population parameters and costs (2019 - 2023)
Year
  2019 2020 2021 2022 2023
Population growth 12 532 012 12 733 778 12 938 792 13 147 106 13 358 775
Increasing CPR (5%) 0.5760 0.58 0.5820 0.5850 0.5880
Average cost (5% inflation) (ZAR) 239.77 251.75 264.34 277.56 291.44
Number using contraceptives 7 218 439 7 372 857 7 530 377 7 691 057 7 854 959
Number demanding contraceptives 9 436 605.37 9 588 534.72 9 742 910.13 9 899 770.98 10 059 157.30
Total current use cost (ZAR) 1 730 729 996 1 856 141 801 1 990 587 730 2 134 715 260 2 289 218 068
Total cost (demanded) (ZAR) 2 262 568 901 2 413 946 073 2 575 451 135 2 747 761 693 2 931 600 690
CPR = contraceptive prevalence rate.
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Similarly, the total cost for Jadelle when premature removals are 
taken into consideration almost triples, from ZAR3.8 million to 
ZAR10.2 million (Table 7).
Discussion
This article considers the financial impact of scaling up modern 
contraceptives in SA. Owing to the challenges that SA has experienced 
with rolling out LARCs,[9,11,12] the current and future impact on the 
national budget of continued premature removals of implantable 
contraceptives was analysed. 
The results show that the total spend on contraception in SA is 
substantial, with base-case costs of current contraceptive use in 2018 
estimated to be ZAR1.64 billion. This is ~1% of the national health 
budget, and about ZAR29 per capita at current population estimates. 
Injectable contraceptives account for ~47% of the total costs. To meet 
the total demand for family planning, SA would have to spend ~30% 
more than the estimate for current contraceptive use. By the year 
2023, the ‘current use’ of modern contraceptives would increase to 
ZAR2.2 billion, and fulfilling the total demand for family planning 
would require ZAR2.9 billion.
Table 5. Five-year projection of population parameters and cost for Implanon and Jadelle, assuming 100% normal removal rate
Year
2019 2020 2021 2022 2023
Implanon
Average cost (5% inflation) (ZAR) 123.63 129.81 136.30 143.12 150.27
Number using 453 069.85 474 175.20 496 263.70 519 381.15 543 575.49
Number demanding 578 053.84 587 360.50 596 817.01 606 425.76 616 189.22
Total current use cost (ZAR) 56 013 304.46 61 553 700.83 67 642 109.72 74 332 736.23 81 685 146.98
Total cost (demanded) (ZAR) 71 465 152.34 76 246 528.36 81 347 802.33 86 790 377.05 92 597 087.23
Jadelle
Average cost (5% inflation) (ZAR) 76.30 80.12 84.12 88.33 92.75
Number using 50 341.09 52 686.13 55 140.41 57 709.02 60 397.28
Number demanding 64 228.00 65 262.28 66 313.00 67 380.64 68 465.47
Total current use cost (ZAR) 3 841 205.19 4 221 147.05 4 638 669.78 5 097 490.59 5 601 694.34
Total cost (demanded) (ZAR) 4 900 841.27 5 228 732.05 5 578 560.37 5 951 793.95 6 349 998.73
Total LARCs
Total current use cost (ZAR) 59 854 509.65 65 774 847.89 72 280 779.51 79 430 226.81 87 286 841.32
Total cost (demanded) (ZAR) 76 365 993.61 81 475 260.41 86 926 362.71 92 742 171.00 98 947 085.95
LARCs = long-acting reversible contraceptives.
Table 6. Five-year projection of population parameters and cost for Implanon, assuming 50% early removals
Year
2019 2020 2021 2022 2023
Early removals
Average cost (5% inflation) (ZAR) 330.59 347.12 364.48 382.70 401.83
Number using 226 534.92 237 087.60 248 131.85 259 690.58 271 787.74
Total cost (current use) (ZAR) 74 890 209.33 82 297 760.95 90 438 009.43 99 383 427.38 109 213 655.86
Normal removals
Average cost (5% inflation) (ZAR) 123.63 129.81 136.30 143.12 150.27
Number using 226 534.92 237 087.60 248 131.85 259 690.58 271 787.74
Total cost (current use) (ZAR) 28 006 652.23 30 776 850.42 33 821 054.86 37 166 368.11 40 842 573.49
Total cost (current use) (ZAR) 102 896 861.56 113 074 611.37 124 259 064.29 136 549 795.50 150 056 229.35
Table 7. Five-year projection of population parameters and cost for Jadelle, assuming 50% early removals
Year
2019 2020 2021 2022 2023
Early removals
Average cost (5% inflation) (ZAR) 330.59 347.12 364.48 382.70 401.83
Number using 25 170.55 26 343.07 27 570.21 28 854.51 30 198.64
Total cost (current use) (ZAR) 8 321 134.37 9 144 195.66 10 048 667.71 11 042 603.04 12 134 850.65
Normal removals 
Average cost (5% inflation) (ZAR) 76.30 80.12 84.12 88.33 92.75
Number using 25 170.55 26 343.07 27 570.21 28 854.51 30 198.64
Total cost (current use) (ZAR) 1 920 602.60 2 110 573.53 2 319 334.89 2 548 745.29 2 800 847.17
Total cost (current use) (ZAR) 10 241 736.97 11 254 769.19 12 368 002.61 13 591 348.34 14 935 697.82
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The use of implantable contraception is currently about 3%,[10] 
and the current spend is estimated at ZAR54 million (2018). 
Assuming a normal removal rate, the use of implants is projected 
to increase by 20% during the 5-year period between 2019 and 
2023, with an estimated 46% increase in costs. Premature removals 
affect both the demand for and cost of contraception. The demand 
decreases, but the total cost increases. For example, the cost of early 
removal of Implanon is estimated at ZAR75 million, with total 
contraception costs estimated at ZAR102 million in 2019, compared 
with ZAR56 million when a normal removal rate is applied.
Most studies that project the costs of family planning do not take 
into account the challenges of scaling up modern contraceptives.[13,14,22] 
The challenges are many, and include issues on both the demand 
and supply sides, such as concerns over side-effects, opposition 
from partners, inadequate logistics and insufficiently trained health 
workers.[23-25] The costs of addressing these challenges are likely to 
be substantial. In this current analysis, we only considered the cost 
of premature removals for implantable contraceptives. Other costs 
related to side-effects associated with this contraceptive method,[26] for 
example, are not taken into account. What we provide in this analysis is 
probably an underestimate of the full costs of contraceptive use.
The analysis in this article, however, is useful in that it provides 
costing and budgeting perspectives and makes the case for conducting 
assessments of new health technology interventions before they 
are introduced.[27] Appropriate economic evaluations should also 
probably include assessments of costs related to training, sensitisation 
and deployment. Technologies should also be targeted at population 
subgroups. In the case of implantable contraception, these devices 
should be provided to women who intend and are likely to use them 
for the entire prescribed period. While it is not easy to predict the 
biological and physiological reactions to contraception, users must 
be given full information on the possible consequences of the various 
contraceptive alternatives, to enable them to make better choices 
about family planning methods. These investments in sensitisation 
and education may initially be substantial, but they could be cost-
saving in the long term.
Contraception is widely accepted to be beneficial and to have a 
positive effect on economic development. However, family planning 
should not be provided ‘at all costs’, and caution must be exercised 
when scaling up ‘beneficial’ interventions. In a country like SA, the 
opportunity cost of resource use is high, necessitating the need for 
evidence-based priority setting. Policymakers must move away from 
allocation of resources based on clinical effectiveness and safety 
alone. In this article, we show the importance of cost considerations 
in the planning process. While the analysis has its limitations, and 
even in instances where data challenges abound, useful and robust 
budget assessments can be provided to inform decision-making. 
More health systems research is need to establish the determinants of 
early contraceptive removal and its economic impact.
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